Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P o0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.
INTRODUCTION
Salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation (ASCT) has become the standard second-line treatment in chemosensitive diffuse large B-cell lymphoma (DLBCL) patients.
1,2 Addition of rituximab to salvage regimens could improve pre-and post-transplantation response rates and failure-free survival. 3 However, the impact of rituximab on overall survival (OS) after salvage is less consistent compared with that in first-line treatment. 2, [4] [5] [6] In the same population, the International CORAL study has shown no difference between two rituximab-containing salvage regimens -rituximab-dexamethasone, cytarabine, cisplatin (R-DHAP) and rituximab-ifosfamide, etoposide and carboplatin (R-ICE)-and no benefit for rituximab maintenance after ASCT. 7, 8 Overall, only 50% of the patients could proceed to ASCT, mainly because of insufficient response to second-line treatment. Factors that negatively affected survival included prior treatment with rituximab, early relapse o 12 months and a secondary ageadjusted IPI (IPI) score of 2-3. 7, 8 Still, even in the latter patients with poor prognosis relapses, ASCT remains the standard of care if patients can achieve CR/PR pretransplantation. [9] [10] [11] We were interested in the characteristics and survival of patients included in the CORAL study, who did not fulfill the protocol strategy at the time of evaluation before transplant. Clinicians had no per-protocol recommendation, except to complete a dedicated form at the time of withdrawal to record what was happening. Patients received modalities ranging from oral palliative chemotherapy to experimental drugs or IV polychemotherapy. Depending on patient response and local situation, there was sometimes an attempt to consolidate with ASCT or allogeneic stem cell transplantation (allo-SCT). No large set of data on DLCBL has been published so far in this situation. The data are observational data in the real life and should help the clinician face this situation.
PATIENTS AND METHODS

Study design and patient selection
The CORAL study was a phase III, multicenter, randomized trial that compared the efficacy of three R-ICE or R-DHAP cycles, followed by ASCT with or without rituximab maintenance in patients aged 18-65 years with previously treated DLBCL. Details of inclusion criteria, treatment, assessment of response and monitoring have been reported previously. 7, 8 In total, between July 2003 and June 2008, 477 patients were randomly assigned to R-ICE (n = 243) or R-DHAP (n = 234). A total of 255 patients who achieved CR, PR or stable disease (SD) after the third cycle of salvage treatment with adequate stem cell collection received consolidation with BEAM (carmustine, etoposide, cytarabine, melphalan), followed by ASCT. Overall, 222 patients did not proceed to planned transplantation according to the protocol because of an event leading to withdrawal between cycle 1 and scheduled ASCT. They were qualified as 'failures' relative to the CORAL strategy and prospectively recorded (protocol amendment) on a special form with the date, reasons for withdrawal, site of disease and new treatments. Among these patients, 6 withdrew their consent and 13 died before ASCT. The present report thus focuses on the 203 remaining patients who did not proceed to per-protocol ASCT and who were candidates for a third-line regimen (Figure 1 ). Their preliminary data have been reported previously. 12 The CORAL study was registered under ClinicalTrials.gov. Data were monitored centrally by the Lymphoma Academic Research Organization (LYSARC). All patients had given written informed consent to participate and to provide tissue material for biologic studies.
Methods
Investigators were surveyed to update their patient status. Patient characteristics, time between CORAL inclusion and failure, type of thirdline regimen, response to third-line treatment, response by CORAL arm (R-ICE or R-DHAP) and OS were collected. IPI was calculated based on characteristics at CORAL failure ('tertiary' IPI). Third-line treatments were grouped by major categories: ICE-type, DHAP-type, gemcitabine-containing, dexa-BEAM-like, CHOP-like, cyclophosphamide, doxorubicin, vincristine, prednisone or acute lymphoblastic leukemia (ALL)-type protocols, and a heterogeneous group of miscellaneous treatments (including lenalidomide, vincristine, bleomycin, fludarabine, bendamustine, in monotherapy or in various combinations). Gemcitabine was mostly combined with vinorelbine, oxaliplatin, dacarbazine or cyclophosphamide. Use of immunotherapy with third-line chemotherapy was recorded when available. All patients had been previously exposed to rituximab in first-and/or secondline treatment.
Evaluations and analyses
Response was investigator assessed by conventional methods that included CT scan using the International Working Group criteria. 13 Progression-free survival (PFS) and event-free survival (EFS) after thirdline treatment were not taken into account because it was anticipated that these results would be less reliable, and the initial CORAL report showed that over 90% of deaths were lymphoma-related. 7 Thus, only the OS is given and is defined as the time from the date the patient was declared as having failed CORAL induction until death. All patients with survival data available were taken into the analysis, and median follow-up was 30.1 months.
Histological material was only available in a subset of patients to assess tumor biology. Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) were performed as previously reported and were centrally reviewed.
14 Cell of origin (COO) was defined according to the algorithm published by Hans et al.
15
The Kaplan-Meier method was used to estimate OS. Wilcoxon's signedrank test or the χ 2 test was used to compare patient characteristics. Cox regression analysis was used to calculate the hazard ratio (HR) between different patient categories. All reported P-values are two-sided, and Po0.05 was considered significant. All analyses were carried out with SAS 9.2 software (SAS Institute, Cary, NC, USA).
RESULTS
Patient characteristics
Among the 203 patients, 170 (83.7%) had been removed from the CORAL salvage strategy with R-DHAP/ICE for an event characterized as 'treatment failure', 19 (9.4%) for treatment toxicity, 1 (0.5%) for major protocol violation and 13 (6.4%) for various other reasons. This means that a proportion of the 203 patients were in response (CR, n = 26; PR, n = 30) at CORAL withdrawal. Reasons for qualifying a responding patient as 'treatment failure' included toxicity, failure to mobilize stem cells, radiotherapy given or investigator decision because of residual mass present. Patient characteristics at CORAL withdrawal are listed in Table 1 . Before CORAL inclusion, 57.6% had first remission duration o 12 months. IPI at second failure was mostly 2-3 in the 52.2% of the patients for whom this information was available (88/203). ICE-type, DHAPlike and gemcitabine-containing regimens were given in 18.5%, 18% and 13.8% of the patients, respectively (unknown regimen in 37 patients). A majority of patients (n = 135) received three or more cycles, whereas 56 received 1 or 2 salvage cycles. Among the 203 patients, 64 (31.5%) were eventually transplanted, mostly with ASCT (n = 56) but some with allogeneic SCT (n = 8). The transplanted patients had significantly lower IPI at failure and were better responders after third-line salvage regimens (CR/PR in 68.8%) compared with 31.2% in non-transplanted patients (P o 0.001).
Tumor biology Immunohistochemical expression of BCL2 and C-MYC in tumor cells was observed in 27/105 (25.7%) and 10/27 (37%) of the evaluable patients, respectively. Among tumor samples displaying interpretable FISH signals, BCL2/18q21 and c-MYC/8q24 gene rearrangements were found in 13/57 (22.8%) and 10/54 (18.5%), respectively. On the basis of the algorithm of Hans, 15 47.1% (48/102) of the patients were classified as germinal center B-celllike and 52.9% (54/102) as non-germinal center B (Table 1) . 
Outcome after third-line DLBCL
Response to third-line regimen. After third-line regimen, response was assessable in 166/203 patients (unknown information in 27, no evaluation performed in 17). For evaluable patients, CR/CR unconfirmed (CRu) and PR rates were 33.1% (55/166; 95% confidence interval: 26.0; 40.8) and 14.5% (24/166; 95% confidence interval: 9.5; 20.7), respectively, for an overall response rate (ORR) of 47.6%. In the intent-to-treat analysis on 203 patients, ORR to third-line chemotherapy was 39%, with 27% CR/CRu and 12% PR. As shown in Table 2 , breakdown of response to third-line regimen according to disease status at CORAL withdrawal shows that responses were observed in all subgroups even among 112 evaluable patients with SD/progressive disease (PD); ORR was 38% with 27 CR/CRu and 16 PR. ORR rates according to the type of third-line regimen were 51.7% after ICE-type, 41.4% after DHAPtype, 13.6% after gemcitabine-containing, 53.3% after dexa-BEAM and 46.2% after CHOP-like regimens. Among patients included in the R-ICE arm of CORAL, 26 received a DHAP-like regimen as thirdline treatment, and their ORR was 42.3%. Conversely, in patients who failed with R-DHAP, 23 were rescued with an ICE-like regimen as third-line treatment, and 43.5% responded.
Survival. Median OS of the entire population was 4.4 months (Figure 2a ), corresponding to a 1-and 2-y OS of 23% and 15.7%, respectively. OS was not significantly different (Supplementary Data and Supplementary Figure 1) according to the reason for CORAL withdrawal (treatment failure, toxicity, protocol violation, others). The outcomes in patient subgroups are displayed in Table 3 . OS was not significantly different according to the type of treatment (Supplementary Data and Supplementary Figure 2 ) and the number of cycles given (not shown). Third-line immunotherapy in 33% of patients (56/116) did not influence the outcome. OS was significantly better in patients with tertiary IPI 0-2 (median, 10.3 months; HR = 3.2) compared in those with tertiary IPI42 (median, 3.2 months) (Figure 2b) . Median OS for patients who achieved CR/CRu, PR and for those who did not respond (SD/PD) to third-line salvage regimens were highly significantly different (Table 3 and Figure 2c ). Patients with SD/PD had a 1-y OS of 8.3% compared with 70.0% for CR/CRu patients (HR = 6.4, P = 0.0001), whereas those with PR had a 1-y OS of 44.4% compared with 70.0% for CR/CRu patients (HR = 2.7, P = 0.01).
Median OS was 11.1 months in patients who were eventually transplanted compared with 3.3 months in those who were not (Po0.0001, log rank, 2.467) (Figure 3 ), corresponding to a 2-y OS of 33.9% and 9.3%, respectively. Survival was not different between ASCT (median, 11.5 months) and allogeneic transplantation (median, 7.9 months, P = 0.3650, log rank, 1.553; Supplementary Data and Supplementary Figure 3) . The proportion of patients eventually transplanted according to response category was 54% (30/55) in CR/CRu, 58% (14/24) in PR and 22% (19/87) in SD/PD patients. Interestingly, the median OS was not reached in patients who achieved CR/CRu after a third-line regimen and who received further ASCT (1-y OS of 88.4%, not shown).
A subanalysis was performed on patients who were removed from CORAL for no response to first salvage therapy (SD/PD patients, n = 135; Table 2 ). With outcome information available for 133 of them, OS was 3.6 months. After third-line salvage regimens, 44 of them (32.6%) could eventually be transplanted (ASCT, n = 37; allogeneic SCT, n = 7) and their OS was 10.6 months as compared with 3.2 months (HR, 3.0) in those who could not be transplanted ( Figure 4a) . As for the entire population, in this subgroup of refractory patients, median OS for those who achieved CR/CRu (n = 27, median not achieved), PR (n = 16, 11.8 months) and for those who did not respond (n = 69, 3.4 months) to third-line salvage regimens were highly significantly different (Figure 4b) .
OS according to IHC and FISH could be determined in a limited number of patients depending on material availability. OS was not different in patients with (n = 26, median, 4.4 months) vs without BCL2 overexpression (n = 75, median, 5.0 months, P = 0.3443, log rank, 1.286) (Supplementary Data and Supplementary Figure 4) . OS was similar between patients with vs without C-MYC overexpression, but only 26 patients could be studied. OS was reduced in patients carrying BCL2/18q21 rearrangement (median, 3.2 months) relative to those without (median, 7.7 months, Abbreviations: allo-SCT = allogeneic SCT; ASCT = autologous stem cell transplantation; F = female; GC = germinal center; IPI = International Prognosis Index; M = male. a Number of patients for whom information was available. Abbreviations: CR = complete remission; CRu = CR undetermined; NA = not applicable; NE = not evaluable; PD = progressive disease; PR = partial remission; SD = stable disease; UNKN = unknown.
Outcome after third-line DLBCL E Van Den Neste et al P = 0.0267, log rank, 2.476) (Supplementary Data and Supplementary Figure 5) . Median OS in patients with and without c-MYC/8q24 rearrangement was 3.5 months (n = 10) and 7.5 months (n = 42), respectively (P = 0.821, log rank, 1.108). In FISH analysis, only six patients had concurrent rearrangements of BCL2 and C-MYC (double hit). There was no OS difference according to GC (n = 45) vs non-GC subtype (n = 53) according to Hans score (Supplementary Data and Supplementary Figure 6) . To explore the impact of transplantation, a multivariate analysis was performed. The Cox model retained included the following factors: sex, age 455 years, IPI at CORAL failure (tertiary IPI) and transplantation performed (yes or no). Response to salvage was not included because this covariate was totally embedded within the transplantation covariate. In this model, tertiary IPI 42 and ability to perform transplantation were independently associated with OS (Po 0.0001, HR, 2.74 and P = 0.0002, HR, 2.667, respectively). This analysis could be performed on 115 patients for whom all data were available.
DISCUSSION
Overall, DLBCL patients who progress or do not respond after two lines of treatment are unlikely to respond to further treatment with standard chemotherapy and have a dismal prognosis. Our analysis, based on OS, points to a minority of patients who, nevertheless, can achieve long-term disease control after third-line salvage regimens. The data presented here are from a unique cohort of patients prospectively studied within a salvage protocol and relate what is happening in real life. Even with the limitation of missing data, this cohort is the largest ever described in that situation and provides interesting parameters, which can be validated in future studies to better describe who could be eligible for experimental third-line salvage regimens. Lower IPI at relapse ('tertiary' IPI) and ability to eventually perform transplantation were independently associated with improved outcome in DLBCL patients failing the CORAL platform. Our study thus demonstrates the value of IPI in third-line treatment, as has been shown in second-line treatment, 8 and in relapse after ASCT. 16 The impact of transplantation should be interpreted in light of the fact that more transplanted patients had achieved response after third-line salvage regimens. This emphasizes the main limitation of these transplant strategies because a significant level of response remains a prerequisite for ASCT and because further improvement with current chemotherapies appears doubtful in the absence of new drugs. Thus, bridging to intensification and transplantation can remain a valid strategy, as previously shown for patients responding to second-line treatment. 7, 17, 18 Allo-SCT could be considered in our study population, and recently an encouraging OS of 47% at 1 year was reported in aggressive lymphoma relapsing o 12 months after last line and treated with lymphomadirected myeloablative conditioning followed by allo-SCT. 19 However, most experts would restrict this option to patients relapsing after ASCT. [20] [21] [22] [23] Overall, the proportion of allo-SCT in the present analysis was too small to make any recommendation regarding this option.
There is limited information on outcome after third-line treatment in DLBCL. Elstrom et al. 24 retrospectively reported 24 patients receiving a third-line regimen and showed a survival of 10 months, and improvement (HR, 0.42) in those responding and a median OS of 4 months among non-responders. Seshadri et al. 25 reported 73 patients who received third-line salvage chemotherapy after failure of platinum-containing salvage, which was similar to our study population, although only 19% of them had received prior rituximab. Ten of them (14%, nine PRs) responded to thirdline treatment. There was a trend for responding patients to have a lower IPI at second progression. Eight of them could be transplanted, and their PFS at 2 years was 31%, comparable to that of patients undergoing transplantation after second-line treatment. Simpson et al. 26 reported a 52% ORR, with 14% (3/21) CR, after ICE in DHAP-failing patients. However, most of the responses (8/11) were observed in patients who were in SD after DHAP. Patients who responded to ICE experienced an OS benefit compared with non-responders (P = 0.01). Overall, 43% proceeded to transplantation, and 29% displayed long-term survival. 26 Ardeshna et al. 27 reported that second-line salvage regimens are not warranted in patients who progress after first-line salvage regimens, but can be of value if a some response is obtained, emphasizing that patient response to preceding therapy has a role in choosing the sequence. In our study, poor response to first salvage (inadequate PR or SD) could be completed by third line to reach transplantation. Nevertheless, even in PD/SD patients the ORR was 38% and offers a bridge to transplant in Outcome after third-line DLBCL32% (44 patients). However, it should be pointed out that response was not evaluated with positron emission tomography scan and that characterization of poor responders could be misleading. Biological changes resulting in cross-resistance to classical agents might contribute to the poor outcome in refractory DLBCL patients. Approximately 20% of our patients had the chromosomal break point c-MYC/8q24, which was similar to that reported at first relapse in the CORAL study, but apparently higher compared with that reported in first-line DLBCL (7% in the report by Valera et al. 28 ). 14 In our study, C-MYC rearrangement, which is associated with worse PFS and OS in patients included in the CORAL study, did not reach significance, 14 although it was observed in a smaller number of patients.
Type of salvage regimen was not clearly associated with different outcomes. Interestingly, patients who shifted from DHAP-type to ICE-type or vice versa could undergo significant response (with~25% CR). Until now, no salvage regimen has been definitively superior to another in a randomized study. Compared with DHAP as second-line treatment, treatment with GDP administered before high-dose chemotherapy and ASCT was non-inferior but was associated with fewer adverse events, better preservation of patient-reported quality of life and less frequent hospitalization. Still, GDP did not increase the proportion of patients who could proceed to transplantation, which remains a major drawback. 11 Overall, it is unlikely that these three primary regimens (DHAP, ICE, GDP) will remain standard in the future with the development of new drugs. 29 Innovative new combinations should be evaluated.
In conclusion, in a proportion of DLBCL patients failing secondline R-DHAP/ICE, if tertiary IPI is low and/or if they are chemosensitive to third-line treatment, a classical approach of trying to consolidate with transplantation may be beneficial.
Patients not belonging to these groups are candidates for alternative approaches. These data can serve as a baseline and should help clinicians in evaluating new treatments. Multiple new agents targeting various pathways in various combinations hold promise for improving survival in DLBCL. [30] [31] [32] [33] Outcome after third-line DLBCL
